The Genomics in Cancer Care Market is broadening its clinical footprint beyond advanced solid tumors into hematologic malignancies, hereditary cancer syndromes, and population-level risk stratification. With market size projected to surge from the mid–tens of billions in 2025 to well over USD 100 billion by 2035, genomics is touching nearly every stage of the cancer continuum.

In hematologic cancers, genomics is indispensable. Mutational panels guide risk stratification, prognostication, and therapy choice in leukemias, lymphomas, and myeloma. Genomic tests identify candidates for targeted drugs, stem cell transplantation, or MRD-guided treatment intensification or de-escalation.

Hereditary cancer testing is another fast-growing segment. Germline genomic tests help identify individuals at high risk for breast, ovarian, colorectal, prostate, and other cancers due to inherited mutations (e.g., BRCA1/2, Lynch syndrome genes). This enables tailored screening, preventive strategies, and cascade testing of family members, shifting focus from treatment alone to risk reduction.

FAQs
Q1. Where is genomics used beyond advanced solid tumors?
In blood cancers, hereditary cancer syndromes, and population-level risk assessment.

Q2. Why is hereditary testing growing?
It finds high-risk individuals early, enabling preventive care and tailored screening strategies.

Tags: hematologic malignancy genomics, hereditary cancer testing, risk stratification, cancer prevention, genomics in cancer care, germline testing, tumor profiling